YARW (Yarrow Bioscience) Ending Cash Position: $22.93 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
13 GF Score
Price $25.39
View Full Analysis

What is Yarrow Bioscience Ending Cash Position?

Yarrow Bioscience YARW -2.75% 13 Ending Cash Position is $22.93 Mil as of Jun. 2026. GuruFocus rates YARW with a GF Score™ of 13/100.

Yarrow Bioscience's Ending Cash Position for the quarter that ended in Jun. 2026 was $22.93 Mil.

Yarrow Bioscience's quarterly Ending Cash Position increased from Dec. 2025 ($24.03 Mil) to Mar. 2026 ($24.63 Mil) but then declined from Mar. 2026 ($24.63 Mil) to Jun. 2026 ($22.93 Mil).

Yarrow Bioscience's annual Ending Cash Position stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2025 ($24.03 Mil).

Yarrow Bioscience Ending Cash Position Related Terms

Yarrow Bioscience Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience Ending Cash Position Chart

Yarrow Bioscience Annual Data
Trend Dec25
Ending Cash Position
24.03

Yarrow Bioscience Quarterly Data
Jun25 Dec25 Mar26 Jun26
Ending Cash Position 22.05 24.03 24.63 22.93
YARW
13GF Score
Yarrow Bioscience Inc YARW
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Yarrow Bioscience's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=19.926+4.101
=24.03

Yarrow Bioscience's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=24.631+-1.706
=22.93

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $22.93 Mil mean?
Yarrow Bioscience (YARW) has a Ending Cash Position of $22.93 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Yarrow Bioscience and its competitors.
Is Yarrow Bioscience's Ending Cash Position too high?
Yarrow Bioscience's current Ending Cash Position is $22.93 Mil. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's Ending Cash Position compare to CGTX and RANI?
Yarrow Bioscience's Ending Cash Position of $22.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Yarrow Bioscience and its competitors. Yarrow Bioscience's current Ending Cash Position is $22.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current Ending Cash Position of $22.93 Mil. The current Ending Cash Position is $22.93 Mil. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current Ending Cash Position is $22.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score

Get the complete analysis for YARW

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.39
Price